Expert Opinion on Therapeutic Targets最新文献_第7页

Advancing our understanding of molecular targets for hepatic ischemia-reperfusion injury therapy. 推进我们对肝缺血再灌注损伤治疗分子靶点的认识。

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-04-01 Epub Date: 2026-05-10 DOI: 10.1080/14728222.2026.2671677

Siyuan Yao, Jerzy W Kupiec-Weglinski

{"title":"Advancing our understanding of molecular targets for hepatic ischemia-reperfusion injury therapy.","authors":"Siyuan Yao, Jerzy W Kupiec-Weglinski","doi":"10.1080/14728222.2026.2671677","DOIUrl":"10.1080/14728222.2026.2671677","url":null,"abstract":"Introduction: Hepatic ischemia-reperfusion injury (IRI) remains a challenge in liver transplantation (LT), particularly with the increasing utilization of marginal grafts. Driven by ischemic stress and hemodynamic instability, IRI triggers intricate inflammatory responses. There is an urgent need to address this challenge by translating mechanistic insights into clinical practice.Areas covered: This review examines IRI mechanisms across diverse cell types and assesses new therapeutic targets identified in recent preclinical and clinical research. It also addresses the implications of IRI in the context of pre-transplant machine perfusion (MP), highlighting approaches to reduce injury and improve graft function, especially in marginal or high-risk liver grafts.Expert opinion: Hepatic IRI research is evolving despite historical challenges like species variability and reliance on rodent models. Advances in MP and studies on discarded human livers now provide clinically relevant validation platforms. This progress shifts our focus toward a vital goal: salvaging marginal grafts to alleviate the global donor organ shortage. Because the intricate nature of IRI limits single-pathway therapies, comprehensive strategies targeting mitochondria, reactive oxygen species, and hepatoprotection are gaining traction. Additionally, basic research should harness big data to identify therapeutic targets that are both highly translatable and reliable, ensuring more effective clinical solutions.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"383-400"},"PeriodicalIF":5.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential of GPR31 as a target for effective oral vaccination. GPR31作为有效口服疫苗接种靶点的潜力。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-04-01 Epub Date: 2026-03-08 DOI: 10.1080/14728222.2026.2641654

Katsuhiro Nakanishi, Kaito Yukishima, Eiji Umemoto

引用次数: 0

P2 receptors as emerging therapeutic targets in neglected parasitic diseases. P2受体作为被忽视的寄生虫病的新治疗靶点

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-04-01 Epub Date: 2026-05-12 DOI: 10.1080/14728222.2026.2671682

Mariana M Chaves, Nayara Carvalho-Barbosa, Luiz Eduardo Baggio Savio, Robson Coutinho-Silva

{"title":"P2 receptors as emerging therapeutic targets in neglected parasitic diseases.","authors":"Mariana M Chaves, Nayara Carvalho-Barbosa, Luiz Eduardo Baggio Savio, Robson Coutinho-Silva","doi":"10.1080/14728222.2026.2671682","DOIUrl":"10.1080/14728222.2026.2671682","url":null,"abstract":"Introduction: Despite sustained control efforts, neglected parasitic diseases, such as malaria, leishmaniasis, Chagas disease, schistosomiasis, and toxoplasmosis, continue to exert a substantial global burden, driven by high prevalence, restricted therapeutic options, drug-associated toxicity, and the progressive emergence of resistance.Areas covered: Accumulating evidence has positioned purinergic signaling as a central regulatory axis in host-parasite interactions, in which P2 receptors are inherently ambiguous, as their signaling can promote either protective or detrimental immune responses depending on the cellular and microenvironmental context. The activation of the P2X7 receptor encourages inflammasome assembly, proinflammatory cytokine release, and microbicidal activity, aiding parasite elimination, though it can also lead to tissue damage in certain scenarios. Moreover, P2Y receptors regulate immune cell recruitment, cell death, and fibrotic responses, thereby influencing infection progression. Altered expression and function of P2 receptors across parasitic diseases highlight their crucial role in pathogenesis and immune regulation.Expert opinion: This review compiles current evidence supporting P2 receptors as viable therapeutic targets and emphasizes their potential to guide the development of safer and more effective interventions against tropical parasitic diseases.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"371-382"},"PeriodicalIF":5.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emergent RNA targets in cardiovascular disease: likely candidates for treatment development. 心血管疾病中新出现的RNA靶点：治疗发展的可能候选物

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-04-01 Epub Date: 2026-05-28 DOI: 10.1080/14728222.2026.2671679

Veronica Barbi, Maria Anele Romeo, Michela Gottardi Zamperla, Federico Favretto, Sandra Atlante, Alessia Lucotti, Carlo Gaetano, Fabio Martelli

{"title":"Emergent RNA targets in cardiovascular disease: likely candidates for treatment development.","authors":"Veronica Barbi, Maria Anele Romeo, Michela Gottardi Zamperla, Federico Favretto, Sandra Atlante, Alessia Lucotti, Carlo Gaetano, Fabio Martelli","doi":"10.1080/14728222.2026.2671679","DOIUrl":"10.1080/14728222.2026.2671679","url":null,"abstract":"Introduction: Cardiovascular diseases (CVDs) are a leading cause of morbidity and death worldwide, emphasizing the urgent need for innovative diagnostic and treatment strategies. Increasing evidence indicates that noncoding RNAs (ncRNAs) play critical roles in the molecular mechanisms of CVDs by regulating epigenetic networks, transcriptional programs, and post-transcriptional gene expression. Their dysregulation is consistently linked to most cardiovascular conditions, making ncRNAs promising biomarkers and therapeutic targets.Areas covered: Recent advances in RNA-based technologies have ushered in a new era of precision cardiology. Preclinical studies have demonstrated the potent efficacy of RNA modulation in disease pathways. Ongoing clinical trials are evaluating RNA-based drugs that target key cardiovascular regulators, underscoring the high potential of this approach. However, challenges related to delivery, specificity, toxicity, and cardiac uptake remain to be addressed to enable widespread clinical application.Expert opinion: RNA-based therapeutics have proven to be highly promising approaches for innovation in cardiovascular medicine. However, significant technical challenges still need to be addressed. Improving delivery systems, refining RNA chemistry, and establishing reliable biomarkers will be crucial for integrating these approaches into standard clinical practice. Ongoing research and clinical validation are expected to determine the extent to which RNA-based therapies will enhance future CVD treatment.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"343-356"},"PeriodicalIF":5.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of human complement factor H in retinal immune response and the prospects for targeted therapy for age-related macular degeneration (AMD). 人补体因子H在视网膜免疫反应中的作用及年龄相关性黄斑变性（AMD）靶向治疗的前景

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-04-01 Epub Date: 2026-05-21 DOI: 10.1080/14728222.2026.2671685

Anne Wolf, Thomas Clahsen, Thomas Langmann

引用次数: 0

Targeting the NLRP3 inflammasome with antibody-based therapeutics for chronic neurodegenerative diseases. 靶向NLRP3炎性体的抗体治疗慢性神经退行性疾病

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-04-01 Epub Date: 2026-05-21 DOI: 10.1080/14728222.2026.2671675

Jagdeep K Sandhu, Jamshid Tanha, Mehdi Arbabi-Ghahroudi

{"title":"Targeting the NLRP3 inflammasome with antibody-based therapeutics for chronic neurodegenerative diseases.","authors":"Jagdeep K Sandhu, Jamshid Tanha, Mehdi Arbabi-Ghahroudi","doi":"10.1080/14728222.2026.2671675","DOIUrl":"10.1080/14728222.2026.2671675","url":null,"abstract":"Introduction: The NLRP3 inflammasome is a central regulator of innate immunity that becomes aberrantly activated by amyloid-β, hyperphosphorylated tau, and α-synuclein aggregates in chronic neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's disease (PD). Sustained activation drives neuroinflammation, synaptic dysfunction, and neuronal loss, making NLRP3 a compelling therapeutic target.Topics covered: This review summarizes current insights into NLRP3 inflammasome biology in AD and PD, with emphasis on antibody-based interventions. Emerging delivery approaches, such as receptor-mediated transcytosis, nanoparticles, adeno-associated viral vectors, and magnetic resonance-guided focused ultrasound are also examined for their potential to enhance central nervous system (CNS) delivery of NLRP3-targeting antibodies.Expert opinion: Antibody-based NLRP3 inhibitors offer high specificity and favorable safety profile compared with small-molecular-weight inhibitors; however, limited blood-brain barrier (BBB) penetration remains a major challenge. Advances in antibody engineering, modular bi-/multi-specific designs, and targeted CNS delivery platforms may soon enable the development of first-in-class antibodies capable of directly modulating neuroinflammation. To realize this potential, the field should prioritize: (1) developing BBB-penetrant antibody constructs; (2) integrating delivery technologies with target biology; and (3) accelerating translation toward first-in-human studies. Successful implementation could transform therapeutic strategies for AD and PD and extend antibody-based interventions across a broader spectrum of neuroinflammatory disorders.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"309-328"},"PeriodicalIF":5.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147863789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intrinsically disordered AF1 domain of steroid hormone receptors as a novel potential target for endocrine cancers. 类固醇受体固有紊乱的AF1结构域作为内分泌癌的新潜在靶点。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-04-01 Epub Date: 2026-05-22 DOI: 10.1080/14728222.2026.2671681

Raj Kumar

引用次数: 0

An overview of outer membrane protein A (OmpA) as a therapeutic target for Acinetobacter baumannii infection. 外膜蛋白a （OmpA）作为鲍曼不动杆菌感染的治疗靶点的综述。

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-04-01 Epub Date: 2026-05-12 DOI: 10.1080/14728222.2026.2671680

Md Minarul Islam, Man Hwan Oh, Woo Shik Shin, Je Chul Lee

{"title":"An overview of outer membrane protein A (OmpA) as a therapeutic target for Acinetobacter baumannii infection.","authors":"Md Minarul Islam, Man Hwan Oh, Woo Shik Shin, Je Chul Lee","doi":"10.1080/14728222.2026.2671680","DOIUrl":"10.1080/14728222.2026.2671680","url":null,"abstract":"Introduction: The rapid dissemination of drug-resistant Acinetobacter baumannii strains has severely limited available therapeutic options, highlighting the urgent need for novel or alternative treatment strategies.Areas covered: Among the diverse virulence factors of A. baumannii, outer membrane protein A (AbOmpA) has emerged as a key pathogenic determinant. AbOmpA plays a multifaceted role in bacterial pathogenesis by mediating host cell adherence and invasion, biofilm formation, stress tolerance, modulation of host immune responses, and resistance to antimicrobial agents. Recent advances in high-throughput technologies, including proteomics, transcriptomics, and bioinformatics, have significantly expanded our understanding of the structure, function, and pathogenic roles of AbOmpA. Consequently, substantial research efforts have focused on the development of AbOmpA-targeted interventions, such as antimicrobial peptides, small molecule inhibitors, monoclonal antibodies, and vaccines. These approaches have demonstrated promising results in reducing bacterial virulence and disease severity, offering potential strategies to combat drug-resistant A. baumannii infections.Expert opinion: AbOmpA represents a highly promising therapeutic target for the treatment of A. baumannii infections due to its high abundance and conservation, its central role in bacterial pathogenesis, and its lack of homology with human proteins. However, further studies are required to overcome current limitations and to evaluate clinical applicability of AbOmpA-targeted therapies.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"357-370"},"PeriodicalIF":5.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular understanding for therapeutic targeting of hypoxia in breast cancer. 乳腺癌缺氧靶向治疗的分子认识。

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-04-01 Epub Date: 2026-05-12 DOI: 10.1080/14728222.2026.2671683

Andrea Angeli, Claudiu T Supuran

{"title":"Molecular understanding for therapeutic targeting of hypoxia in breast cancer.","authors":"Andrea Angeli, Claudiu T Supuran","doi":"10.1080/14728222.2026.2671683","DOIUrl":"10.1080/14728222.2026.2671683","url":null,"abstract":"Introduction: Breast cancer is one of the most widespread types of cancer, affecting millions of patients worldwide and although significant advances in its therapy have been achieved in the last decades, a large number of death still occur. Triple-negative breast cancer (TNBC) is the subtype associated with aggressive behavior, early metastasis, and limited therapeutic options, resulting in poor clinical outcomes for many affected patients. Many such tumors are frequently hypoxic.Areas covered: Hypoxia is a hallmark of solid tumors, including breast cancers. Molecular events triggered by hypoxia are orchestrated by hypoxia-inducible factors (HIFs), which regulate transcription of genes involved in cell survival, invasion, angiogenesis, and resistance to chemo- and radio-therapy. Apart HIF itself, other potential molecular targets such as prolyl-hydroxylases (PHD), von Hippel-Lindau protein (VHL), monocarboxylate transporters (MCTs), Na+/H+ exchangers (NHEs), vacuolar ATPases (V-ATPase), anion exchangers (AEs), Na+ /HCO3- co-transporters (NBCs), vascular endothelial growth factor (VEGF) and carbonic anhydrases were identified as being involved in tumorigenesis.Expert opinion: HIF-1α inhibitors (topotecan, digoxin, PX-478), hypoxia-activated prodrugs (evofosfamide, apaziquone, porfiromycin, tirapazamine, banoxantrone) and carbonic anhydrase IX/XII inhibitors (SLC-0111) are either used clinically or in clinical development for the management of hypoxic breast cancers.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"401-415"},"PeriodicalIF":5.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Key principles and guidance for the development of lncRNA targeting cancer therapeutics. lncRNA靶向癌症治疗发展的关键原则和指导。

IF 5.1 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-04-01 Epub Date: 2026-05-13 DOI: 10.1080/14728222.2026.2671684

Waleed H Almalki

{"title":"Key principles and guidance for the development of lncRNA targeting cancer therapeutics.","authors":"Waleed H Almalki","doi":"10.1080/14728222.2026.2671684","DOIUrl":"10.1080/14728222.2026.2671684","url":null,"abstract":"Introduction: Long non-coding RNAs (lncRNAs) have emerged as critical regulators of gene expression and cellular behavior in cancer, influencing tumor initiation, progression, metastasis, and therapeutic resistance. Their regulatory complexity and disease-specific expression patterns position them as promising yet challenging therapeutic targets.Areas covered: This review summarizes current knowledge on the biological roles of lncRNAs in cancer and examines emerging therapeutic strategies designed to modulate their activity. The discussion integrates findings from recent genomic studies, functional screening approaches, and preclinical investigations of lncRNA-targeting modalities, including antisense oligonucleotides and other RNA-directed platforms. Key challenges related to target identification, delivery, specificity, and translational development are also addressed.Expert opinion: Although lncRNA-targeting therapeutics remain at an early stage of clinical translation, advances in RNA biology and drug delivery technologies are rapidly expanding their therapeutic potential. A rational framework integrating biological insight with translational considerations will be essential for guiding the development and clinical advancement of lncRNA-based cancer therapies.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"329-342"},"PeriodicalIF":5.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147927917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0